A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial

Jens Kastrup; Erik Jørgensen; Shmuel Fuchs; Sigrid Nikol; Hans Erik Bøtker; Mariann Gyöngyösi; Dietmar Glogar; Ran Kornowski

doi:10.4244/EIJV6I7A140

A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial

Jens Kastrup, Erik Jørgensen, Shmuel Fuchs, Sigrid Nikol, Hans Erik Bøtker, Mariann Gyöngyösi, Dietmar Glogar, Ran Kornowski

76 Citations (Scopus)

Abstract

Genes encoding vascular endothelial growth factor (VEGF) can potentially augment myocardial perfusion in patients with coronary artery disease (CAD). We conducted a randomised, double-blind, placebo-controlled gene therapy study with the adenovirus carrying VEGF121 (BIOBYPASS [AdGVVEGF121.10NH]).

Original language	English
Journal	EuroIntervention
Volume	6
Issue number	7
Pages (from-to)	813-8
Number of pages	6
ISSN	1774-024X
DOIs	https://doi.org/10.4244/EIJV6I7A140
Publication status	Published - 2011

Keywords

Adenoviridae
Aged
Coronary Artery Disease
Double-Blind Method
Exercise Tolerance
Female
Gene Therapy
Gene Transfer Techniques
Genetic Vectors
Humans
Injections
Male
Middle Aged
Myocardium
Tomography, Emission-Computed, Single-Photon
Vascular Endothelial Growth Factor A
Ventricular Function, Left

Access to Document

10.4244/EIJV6I7A140

Fingerprint

Dive into the research topics of 'A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial'. Together they form a unique fingerprint.

Cite this

Kastrup, J., Jørgensen, E., Fuchs, S., Nikol, S., Bøtker, H. E., Gyöngyösi, M., Glogar, D., & Kornowski, R. (2011). A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial. EuroIntervention, 6(7), 813-8. https://doi.org/10.4244/EIJV6I7A140

A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial. / Kastrup, Jens ; Jørgensen, Erik; Fuchs, Shmuel et al.
In: EuroIntervention, Vol. 6, No. 7, 2011, p. 813-8.

Research output: Contribution to journal › Journal article › Research › peer-review

Kastrup, J , Jørgensen, E, Fuchs, S, Nikol, S, Bøtker, HE, Gyöngyösi, M, Glogar, D & Kornowski, R 2011, 'A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial', EuroIntervention, vol. 6, no. 7, pp. 813-8. https://doi.org/10.4244/EIJV6I7A140

@article{168650e7ada0436184710587d32cf1e2,

title = "A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial",

abstract = "Genes encoding vascular endothelial growth factor (VEGF) can potentially augment myocardial perfusion in patients with coronary artery disease (CAD). We conducted a randomised, double-blind, placebo-controlled gene therapy study with the adenovirus carrying VEGF121 (BIOBYPASS [AdGVVEGF121.10NH]).",

keywords = "Adenoviridae, Aged, Coronary Artery Disease, Double-Blind Method, Exercise Tolerance, Female, Gene Therapy, Gene Transfer Techniques, Genetic Vectors, Humans, Injections, Male, Middle Aged, Myocardium, Tomography, Emission-Computed, Single-Photon, Vascular Endothelial Growth Factor A, Ventricular Function, Left",

author = "Jens Kastrup and Erik J{\o}rgensen and Shmuel Fuchs and Sigrid Nikol and B{\o}tker, {Hans Erik} and Mariann Gy{\"o}ngy{\"o}si and Dietmar Glogar and Ran Kornowski",

year = "2011",

doi = "10.4244/EIJV6I7A140",

language = "English",

volume = "6",

pages = "813--8",

journal = "EuroIntervention",

issn = "1774-024X",

publisher = "Europa Edition",

number = "7",

}

TY - JOUR

T1 - A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial

AU - Kastrup, Jens

AU - Jørgensen, Erik

AU - Fuchs, Shmuel

AU - Nikol, Sigrid

AU - Bøtker, Hans Erik

AU - Gyöngyösi, Mariann

AU - Glogar, Dietmar

AU - Kornowski, Ran

PY - 2011

Y1 - 2011

N2 - Genes encoding vascular endothelial growth factor (VEGF) can potentially augment myocardial perfusion in patients with coronary artery disease (CAD). We conducted a randomised, double-blind, placebo-controlled gene therapy study with the adenovirus carrying VEGF121 (BIOBYPASS [AdGVVEGF121.10NH]).

AB - Genes encoding vascular endothelial growth factor (VEGF) can potentially augment myocardial perfusion in patients with coronary artery disease (CAD). We conducted a randomised, double-blind, placebo-controlled gene therapy study with the adenovirus carrying VEGF121 (BIOBYPASS [AdGVVEGF121.10NH]).

KW - Adenoviridae

KW - Aged

KW - Coronary Artery Disease

KW - Double-Blind Method

KW - Exercise Tolerance

KW - Female

KW - Gene Therapy

KW - Gene Transfer Techniques

KW - Genetic Vectors

KW - Humans

KW - Injections

KW - Male

KW - Middle Aged

KW - Myocardium

KW - Tomography, Emission-Computed, Single-Photon

KW - Vascular Endothelial Growth Factor A

KW - Ventricular Function, Left

U2 - 10.4244/EIJV6I7A140

DO - 10.4244/EIJV6I7A140

M3 - Journal article

C2 - 21252014

SN - 1774-024X

VL - 6

SP - 813

EP - 818

JO - EuroIntervention

JF - EuroIntervention

IS - 7

ER -